TherapeuticsMD (TXMD) EBIT (2010 - 2026)

TherapeuticsMD (TXMD) has reported EBIT for 17 consecutive years, with -$816000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 17.41% year-over-year to -$816000.0; the trailing twelve-month figure through Jun 2026 stood at -$4.0 million (down 5.08% YoY), and the FY2025 full-year result was -$4.4 million, up 28.17% from the prior year.
• EBIT retreated to -$816000.0 in Q2 2026 per TXMD's latest filing, from -$723000.0 in the prior quarter.
• Across five years, EBIT topped out at $48.4 million in Q4 2022 and bottomed at -$17.9 million in Q1 2022.
• Historically, EBIT has averaged -$1.1 million across 5 years, with a median of -$1.4 million in 2025.
• The sharpest annual moves came in 2022 and 2025: EBIT jumped 236.87% in 2022, then tumbled 138.04% in 2025.
• Over 5 years, EBIT stood at $48.4 million in 2022, then slumped by 103.33% to -$1.6 million in 2023, then soared by 59.53% to -$652000.0 in 2024, then sank by 138.04% to -$1.6 million in 2025, then surged by 47.42% to -$816000.0 in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$816000.0, -$723000.0, and -$1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.